59989-18-3C#Cc1c[nH]c(=O)[nH]c1=OJOZGNYDSEBIJDH-UHFFFAOYSA-N59989-18-3DTXSID10208696CHEMBL355200CHEBI:177783안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
용도Potent inactivator of Dihydropyrimidine dehydrogenase (DPD).
불러오는 중…